Actively Recruiting
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
Led by M.D. Anderson Cancer Center · Updated on 2026-01-13
13
Participants Needed
1
Research Sites
502 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers better diagnose glioma in patients with brain tumors.
CONDITIONS
Official Title
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent obtained from each participant including healthy volunteers
- Healthy volunteers have no contraindications to MR scanning
- All patients enrolled in Stereotactic RadPath trial (#2011-0370)
- Age over 18 years
- Candidate for cerebral tumor resection with suspected or biopsy-proven primary brain tumor
- Able to understand and give consent
- Agree to undergo MRI including perfusion, diffusion, and spectroscopic imaging within 14 days before procedure
- Glomerular filtration rate (GFR) greater than 60 (or considered for alternate contrast dose if 30-60)
- Willing to give signed informed consent for C13-Pyruvate MR Spectroscopy
You will not qualify if you...
- Unfavorable anatomy preventing safe stereotactic biopsy
- Presence of pacemakers, electronic stimulation devices, metallic foreign bodies or other MR unsafe implants
- Pregnancy
- Claustrophobia not responsive to oral medication
- Prior brain tumor treatment including surgical resection, radiation, or chemotherapy (previous biopsy allowed)
- History of cardiac arrhythmia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
Dawid Schellingerhout
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here